This invention relates to processes for the removal of phosphorous from aqueous waste streams comprising phosphorus-containing compounds produced in the manufacture of glyphosate, in order to meet and typically exceed environmental regulations. More particularly, various embodiments of the present invention relate to the removal of phosphorous-containing compounds utilizing biological treatment system(s), oxidizing agent(s), and/or precipitant(s). The processes of the invention are also applicable to the removal of phosphorous compounds from phosphorous-containing waste streams other than those waste streams resulting from the manufacture of glyphosate.

The present invention relates to compounds represented by formula (I) and formula (II) and a chiral synthesis and chiral isolation method therefor, further relating to a salt and crystal form of the compound represented by formula (I), a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the preparation of a medicament used for the treatment of a viral infectious disease such as hepatitis B. ##STR00001##

The present invention provides an electrolyte solution for a non-aqueous electrolyte battery capable of an exerting high average discharge voltage and an excellent low-temperature output characteristic at −30° C. or lower and an excellent cycle characteristic and an excellent storage characteristic at high temperatures of 50° C. or higher, as well as a non-aqueous electrolyte battery containing the same. The present electrolyte solution comprises a non-aqueous solvent, a solute, at least one silane compound represented by the following general formula (1) as a first compound, and a fluorine-containing compound represented by the following general formula (3), for example, as a second compound.
Si(R.sup.1).sub.a(R.sup.2).sub.4-a  (1) ##STR00001##

The present invention provides an electrolyte solution for a non-aqueous electrolyte battery capable of an exerting high average discharge voltage and an excellent low-temperature output characteristic at −30° C. or lower and an excellent cycle characteristic and an excellent storage characteristic at high temperatures of 50° C. or higher, as well as a non-aqueous electrolyte battery containing the same. The present electrolyte solution comprises a non-aqueous solvent, a solute, at least one silane compound represented by the following general formula (1) as a first compound, and a fluorine-containing compound represented by the following general formula (3), for example, as a second compound.
Si(R.sup.1).sub.a(R.sup.2).sub.4-a  (1) ##STR00001##

A crystalline form of phenyl bis (2,4,6-trimethylbenzoyl) phosphine oxide, with a large particle size, which belongs to a triclinic crystal system and space group P-1. A crystallization method for making the crystalline form of phenyl bis (2,4,6-trimethylbenzoyl) phosphine oxide, comprising adding a solid of phenyl bis (2,4,6-trimethylbenzoyl) phosphine oxide to a solvent and mixing; followed by heating to 50 to 70° C. to achieve complete dissolution; cooling the solution to room temperature; and adding an anti-solvent to the resulting solution to cause precipitation of crystals. The crystals are allowed to grow at a constant temperature for 10 to 60 minutes, so as to give a slurry containing the crystals. Said slurry is subjected to filtration and then drying to obtain the crystalline form of phenyl bis (2,4,6-trimethylbenzoyl) phosphine oxide.

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK.sub.1) receptor. The compounds have the general formula (I):

##STR00001##

The present invention relates to a compound of a novel antiviral nucleoside reverse transcriptase inhibitor, a pharmaceutical composition containing the compound, and preparation and application of the compound. Specifically, disclosed in the present invention are a fused pyrimidine compound as represented by formula (I) and a pharmaceutical composition comprising the compound, or a pharmaceutically acceptable salt, stereoisomer, solvate, hydrate, crystal form, prodrug or isotopic derivative of the compound. The compound of the present invention can be used for treatment and/or prevention of infectious diseases caused by viruses, such as human immunodeficiency virus (HIV), hepatitis B virus (HBV). ##STR00001##

The invention belongs to the technical field of phospholipid processing, in particular to a low-iron hydrous phospholipid and a method for separating low-iron hydrous phospholipids from soybean oil sediments. The main components of low-iron water-containing phospholipids are phospholipids, oil and water; its water content is 70-80 g/100 g; on a dry basis, the content of acetone-insoluble matter is 92.5-95.5 g/100 g; in terms of acetone-insoluble matter, the iron content is less than or equal to 18 mg/kg. The low-iron water-containing phospholipid of the present invention is prepared from soybean oil by a hydration method, and is used to solve the defects of low acetone-insoluble content of the water-containing phospholipid, inability to remove iron ions and the industry's long-term dependence on the solvent method to prepare the powdered phospholipid; At the same time, the method solves the technical problem that “the preparation of powder phospholipid by hydration method cannot realize industrial production”.

A light-absorbing composition includes: a light absorber formed by a phosphonic acid represented by the following formula (a) and copper ion, the light absorber being dispersed in the light-absorbing composition; a phosphoric acid ester allowing the light absorber to be dispersed; and a curable resin. When the light-absorbing composition is applied and cured on one principal surface of a transparent dielectric substrate to form a laminate consisting of a light-absorbing layer being a cured product of the light-absorbing composition and the transparent dielectric substrate, the laminate satisfies predetermined requirements. ##STR00001##

A light-absorbing composition includes: a light absorber formed by a phosphonic acid represented by the following formula (a) and copper ion, the light absorber being dispersed in the light-absorbing composition; a phosphoric acid ester allowing the light absorber to be dispersed; and a curable resin. When the light-absorbing composition is applied and cured on one principal surface of a transparent dielectric substrate to form a laminate consisting of a light-absorbing layer being a cured product of the light-absorbing composition and the transparent dielectric substrate, the laminate satisfies predetermined requirements. ##STR00001##